BioSpace News Archive

CAMBRIDGE, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, announced today it will present at the Cowen & Co. 40 th Annual Health Care Conference on Monday, March 2, 2020 in Boston, Massachusetts and the 30 th Annual Oppenheimer Healthcare Conference on Wednesday, March 18, 2020 in New York. Pre

CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent supplier and manufacturer of hemp cannabidiol (CBD) products, today announced that it will release financial results for the year ended December 31, 2019, after the stock market closes on Tuesday, March 10, 2020.

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, announced today that management will participate in two investor conferences in March.

Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex”) today clarified certain information regarding its stock dividends consisting of two shares of Generex stock for every five shares held, and two shares of NuGenerex Immuno-Oncology for every five shares of Generex.

DURHAM, N.C., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer, will present a corporate overview at the Cowen and Company 40th Annual Health Care Conference on Wednesday, March 4, 2020 at 8:40 a.m. ET in Boston, MA. A live audio webcast of the presentation will be available on the Investor Relations s

Latest Connected Health Technology to Improve Collaboration Among Patients, Care Team, and Physicians

Leaders from The Permanente Federation, The SCAN Foundation and California Health Care Foundation will present “Treating the Other 1%: Americans with Unmet Needs,” a panel on March 17, 2020 at the South by Southwest® Conference in Austin, Texas.

Feb. 26, 2020 13:00 UTC Seattle Genetics to Present at the Cowen 40 th Annual Healthcare Conference BOTHELL, Wash.--( BUSINESS WIRE )-- Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at the Cowen 40 th Annual Healthcare Conference on Tuesday, March 3, 2020 at 9:20 a.m. Eastern Time. The presentation will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors section. About Sea

Feb. 26, 2020 13:00 UTC Taiho’s in-licensing facilitates global development and commercialization of zimberelimab as a monotherapy and as a combination backbone for Arcus’s and Taiho’s oncology portfolios Zimberelimab exhibits clinical activity and a safety profile consistent with those of currently approved anti-PD-1 therapies Broad development program delivering randomized data in 2020 for zimberelimab in multiple novel combinations, including with AB154, Arcus’s a

Feb. 26, 2020 13:05 UTC SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )-- Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a collaboration with SOPHiA GENETICS, leader in Data-Driven Medicine to bring access to the universal SOPHiA Platform for advanced genomic analysis to Twist’s customers, providing the analysis and interpretation of sequencing inform